These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1469083)

  • 1. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.
    Zenobi PD; Jaeggi-Groisman SE; Riesen WF; Røder ME; Froesch ER
    J Clin Invest; 1992 Dec; 90(6):2234-41. PubMed ID: 1469083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.
    Schalch DS; Turman NJ; Marcsisin VS; Heffernan M; Guler HP
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1563-8. PubMed ID: 8263142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
    Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
    Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes].
    Kato M
    Hokkaido Igaku Zasshi; 1998 Nov; 73(6):613-25. PubMed ID: 10036618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
    Cusi K; DeFronzo R
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
    Dunger DB; Acerini CL
    Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.
    Asmar M; Højberg PV; Deacon CF; Hare K; Holst JJ; Madsbad S
    Regul Pept; 2010 Feb; 160(1-3):175-80. PubMed ID: 20005261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
    Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
    Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
    Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of a continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I (rhIGF-I) on glucose and insulin levels in healthy males.
    Morgan JM; Piraino AJ; Saris SD; Capuzzi DM
    Int J Clin Pharmacol Ther; 1994 May; 32(5):235-9. PubMed ID: 7921517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs.
    Douglas RG; Gluckman PD; Ball K; Breier B; Shaw JH
    J Clin Invest; 1991 Aug; 88(2):614-22. PubMed ID: 1864971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
    Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
    Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice.
    Bhat RV; Engber TM; Zhu Y; Miller MS; Contreras PC
    J Pharmacol Exp Ther; 1997 Apr; 281(1):522-30. PubMed ID: 9103540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A.
    Zenobi PD; Glatz Y; Keller A; Graf S; Jaeggi-Groisman SE; Riesen WF; Schoenle EJ; Froesch ER
    Eur J Endocrinol; 1994 Sep; 131(3):251-7. PubMed ID: 7921209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus.
    Vestergaard H; Rossen M; Urhammer SA; Müller J; Pedersen O
    Eur J Endocrinol; 1997 May; 136(5):475-82. PubMed ID: 9186267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.
    Morrow LA; O'Brien MB; Moller DE; Flier JS; Moses AC
    J Clin Endocrinol Metab; 1994 Jul; 79(1):205-10. PubMed ID: 8027228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
    Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
    Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion.
    Zenobi PD; Graf S; Ursprung H; Froesch ER
    J Clin Invest; 1992 Jun; 89(6):1908-13. PubMed ID: 1601998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.